Anti-TNFRSF13C/BAFFR/CD268 Antibody (Ianalumab)
Catalog No.
F1475
Anti-TNFRSF13C/BAFFR/CD268 Antibody (Ianalumab)
Featured Products
Ianalumab (VAY-736) is a humanized, decarboxylated antibody targeting BAFF-R. Ianalumab blocks the interaction between BAFF and BAFF-R, antagonizing BAFF-mediated protection from apoptosis. Ianalumab has antibody-dependent cellular cytotoxicity (ADCC) that is dependent on immunoreceptor tyrosine-based activation motifs (ITAMs)-mediated activation of effector cells.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.44 kDa
Dry ice
1929549-92-7
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
VAY-736, NOV-5
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q96RJ3
Human
Unconjugated
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human GPA33 / A33, Fc Tag at 2 ug/mL can bind ianalumab
TNFRSF13C / BAFFR / CD268
Please avoid freeze-thaw cycles.